DGAP-News

MOLOGEN at SITC 2015: Preliminary data from IMPALA trial confirm mode of action of MGN1703 (news with additional features) - Seite 2

study"

For more information on the Society for Immunotherapy of Cancer Conference
(SITC 2015) please visit the website http://www.sitcancer.org.

About IMPALA
IMPALA is a randomized, international, multicenter, open-label phase III
trial. The study aims to prove that a switch maintenance therapy with an
active immunotherapy leads to an increased overall survival of patients who
have achieved a response during their first line treatment of metastatic
colorectal cancer. The primary endpoint is overall survival and secondary
study endpoints include progression-free survival, toxicity and safety, and
Quality of Life (QoL).

Approximately 540 patients from more than 100 European centers, including
the five major pharma markets, will participate in the study. IMPALA
started to treat the first patients in mid-September 2014.

For more information on the trials IMPACT and IMPALA please visit
www.clinicaltrials.gov.


MGN1703
MGN1703 is an innovative DNA-based TLR9 agonist developed by MOLOGEN that
broadly activates the immune system. This activation can be utilized to
enable the immune system to increase the recognition and combat of cancer
cells. Due to this mechanism of action, it is predicted that MGN1703 can be
applied to a number of diseases.

MOLOGEN AG
With new and unique technologies and active substances, the biotech company
MOLOGEN is one of the pioneers in the field of immunotherapy. Alongside a
focus on immuno-oncology, MOLOGEN also develops immunotherapies for the
treatment of infectious diseases.

The cancer immunotherapy MGN1703 is the company's lead product and
best-in-class TLR9 agonist. Treatment with MGN1703 triggers a broad and
strong activation of the immune system. Due to this mechanism of action,
MGN1703 has the potential to be applied to various indications. MGN1703 is
currently being developed for first-line maintenance treatment of
colorectal cancer (pivotal study) and small cell lung cancer (randomized
controlled trial). Furthermore it is also being investigated in a phase I
study in HIV.

MOLOGEN's pipeline focus is on new innovative immunotherapies to treat
diseases for which there is a high medical need.

MOLOGEN AG is listed on the stock exchange and its headquarters are located
in Berlin, Germany.

www.mologen.com

Memberships in associations:
Biotechnologieverbund Berlin-Brandenburg (bbb) e.V. | BIO Deutschland
e.V. | DECHEMA - Society for chemical technology and biotechnology e.V.
| German industrial association of biotechnology (DIB) | Association for
the Promotion of Science and Humanities in Germany | Association of